Press Release

31 May 2018

FORMA Therapeutics and HitGen Initiate Multiyear Research Collaboration

Watertown, Mass. and CHENGDU, China– May 31, 2018– FORMA Therapeutics and HitGen Ltd. today announced a multiyear research collaboration and license agreement to build and screen proprietary DNA-encoded libraries (DELs). Through this collaborative alliance, scientists from both organizations will contribute innovative library design and screening approaches to identify novel leads against a selected number of FORMA’s therapeutic targets. FORMA will fund the discovery research at HitGen and maintain a world-wide exclusive license for further research and development of any compounds discovered through the collaboration.
28 May 2018

HitGen Announces Completion of RMB 250 Million Series B Fund Raising

28 May 2018, Chengdu, HitGen announces the completion of RMB 250 Million Series B fund raising. This round of fund raising was led by CDH, a leading VC and PE firm in China, and Leadyond capital. According to the company, the proceeds from this round of fund raising will be used to expand and enhance its core drug discovery technology platform, DNA-encoded library design, synthesis and screening, as well as to accelerate the research and development of its therapeutic programs.
07 May 2018

HitGen's Small Molecule IND Receives Approval by CFDA for Clinical Trials

Chengdu, China, May 7, 2018– HitGen Ltd. announced that its novel small molecule Class I/IIb HDAC inhibitor HG146 (Category 1 of new chemical drug) received approval by Chinese Food and Drug Administration (CFDA) to begin the clinical trialsforMultiple Myeloma.
20 April 2018

HitGen Announces Research Collaboration and License Agreement with Simcere

Chengdu, China, Apr 20, 2018, Simcere Pharmaceutical Group (Simcere) and HitGen Ltd (HitGen) announced today that they have entered into a license agreement on innovative drug discovery.
13 March 2018

HitGen and BASF enter DNA-encoded library based research collaboration

Ludwigshafen, Germany, and Chengdu, China, March 13, 2018 –BASFand HitGen Ltd. have entered into a research collaboration to identify novel, small molecule leads for targets of agrochemical interest to BASF.
05 February 2018

NetVation DL Medicine Announces Research Collaboration with Pfizer Inc.

Chengdu, China，February 6th, 2018 NetVation DL Medicine (“DL Medicine”), a privately held biotechnology company based in Chengdu, China, and focused on the discovery and development of novel drug candidates, announced today that it has entered into a two-year research collaboration with Pfizer Inc (NYSE: PFE). Under the terms of the agreement, DL Medicine will screen and collaborate with Pfizer in producing new chemical entities against pre-selected targets from multiple therapeutic areas. As part of the collaboration, Pfizer has taken a financial stake in DL Medicine.
27 November 2017

HITGEN and Boehringer Ingelheim Enter DNA-Encoded Library Based Drug Discovery Research Collaboration

Chengdu, China，November 23rd 2017, HitGen Ltd announced that the company has entered into a drug discovery research collaboration with Boehringer Ingelheim to identify novel small molecule leads for targets of interest to Boehringer Ingelheim. In this collaboration, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to discover novel leads for Boehringer Ingelheim. Under the terms of the agreement, HitGen will receive upfront payments, and be eligible for milestone payments from Boehringer Ingelheim. Specific financial details were not disclosed.
11 September 2017

HITGEN and TAKEDA Enter DNA-Encoded Library Based Drug Discovery Research Collaboration

Chengdu, China，Sep. 11th, 2017, HitGen Ltd announced that the company has entered into a research collaboration with Takeda Pharmaceutical Company Limited to discover novel small molecule leads for multiple targets in Takeda’s therapeutic areas of interest. According to the agreement, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to discover novel leads which will be licensed exclusively to Takeda. Under the terms of the agreement, HitGen will receive upfront compensation, and be eligible for milestone payments from Takeda. Specific financial details were not disclosed.
05 September 2017

Cocrystal Pharma, HitGen and InterX Enter into Research Collaboration

ATLANTA, GA and BOTHELL, WA—(Marketwired) – September 5, 2017 - Cocrystal Pharma, Inc. (OTCQB: COCP) today announced that it has entered into a research collaboration with HitGen, Ltd., a private biotechnology company and InterX, Inc., a private computer software company to develop small molecule drug candidates against several undisclosed targets.
07 August 2017

HitGen and LEO PHARMA Enter Research Collaboration

Chengdu, China，7th August, 2017, HitGen Ltd announced that the company has entered into a multi-target multi-year collaboration with LEO Pharma A/S , to discover novel small molecule leads for multiple therapeutic targets of interest to LEO Pharma. According to the agreement, HitGen will use its advanced technology platform, based on DNA-encoded library design, synthesis and screening to discover novel leads which will be licensed exclusively to LEO Pharma. Under the terms of the agreement, HitGen will receive an upfront payment and be eligible for milestone payments from LEO Pharma.

News

Press Release

Thanks for reading!